AWAKN LIFE SCIENCES CORP - AWKNF STOCK NEWS

Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has partnered with the University of Nottingham for in vivo testing of its aminoindane New Chemical Entity (NCE) pre-clinical program. The study, led by Dr. Madeleine King, will evaluate Awakn's co-lead aminoindane series for its potential to enhance social cognition and pro-social behaviors.

The research will use the Social Transmission of Food Preferences (STFP) test in rodent models over a two-month period, with results expected by the end of 2024. This collaboration follows Awakn's recent partnership with Eurofins Discovery for in vitro pharmacology testing of the same aminoindane series.

Awakn's aminoindane NCE program, developed with Graft Polymer (UK) Plc, aims to create new therapeutic options for trauma-related mental health disorders, particularly PTSD, which affects approximately 13 million adults in the U.S. and 20 million individuals across the U.S., UK, and Europe.

Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has selected Eurofins Discovery to conduct initial pharmacology testing for its co-lead aminoindane series as part of its New Chemical Entity (NCE) pre-clinical program. This collaboration marks a significant milestone in Awakn's mission to develop next-generation therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (AUD).

The NCE program, developed in partnership with Graft Polymer (UK) Plc, aims to create a new class of therapeutics for trauma-related mental health disorders, such as Post-Traumatic Stress Disorder (PTSD). This condition affects approximately 13 million adults in the U.S. and 20 million collectively in the US, UK, and key European markets.

Prof. David Nutt, Awakn's Chief Research Officer, expressed confidence that this collaboration will accelerate their path to delivering groundbreaking treatments. CEO Anthony Tennyson emphasized the potential impact of the NCE program for patients across North America and beyond.

Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has announced an upsizing of its non-brokered private placement financing from $1,000,000 to $2,000,000. The company has closed a fourth tranche of the offering, issuing 857,143 units at $0.46 per unit, raising an additional $394,286 for a combined total of $1,117,142. Each unit consists of one common share and 0.75 of a warrant, with each whole warrant allowing the purchase of one common share at $0.63 for five years. The proceeds will be used for general working capital. Securities issued are subject to a four-month hold period and applicable resale rules.

Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has announced significant progress in its pre-clinical program for developing therapeutics for trauma-related mental health disorders, particularly Post-Traumatic Stress Disorder (PTSD). The program, executed in collaboration with Graft Polymer, has identified two chemical series as co-leads for further development and established their synthesis pathways. Awakn has selected Charnwood Discovery as its synthesis partner and filed a provisional patent for a new class of aminoindane chemical entities and their derivatives. This progress aims to address the needs of approximately 13 million adults in the U.S. and 20 million collectively in key international markets affected by PTSD.

Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has announced the screening of the first patient in its landmark 'MORE-KARE' Phase 3 trial of AWKN-001 for severe Alcohol Use Disorder (AUD). This trial, co-funded by the UK's Medical Research Council, National Institute for Health and Care Research, and Awakn, aims to evaluate the effectiveness of ketamine-assisted therapy for AUD.

The study will assess the impact of a single treatment cycle of AWKN-001, which combines intravenous ketamine with psycho-social support. The primary endpoint is the reduction in heavy drinking days over six months post-treatment. With a total cost of £2.4 million (CAD 4.2 million), this is the largest study of its kind and could potentially revolutionize AUD treatment.

Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has closed a third tranche of its non-brokered private placement, issuing 428,571 units at $0.46 per unit for additional gross proceeds of $197,143. Each unit comprises one common share and 0.75 of a warrant, with each whole warrant allowing the purchase of one common share at $0.63 for five years. The company has also extended the expiry date of 5,610,920 warrants with an exercise price of $0.68. Proceeds will fund general working capital. The securities are subject to a four-month hold period, and the warrant extension includes a related party transaction exempt from formal valuation and minority approval requirements.

Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has provided an update on its aminoindane new chemical entity (NCE) patent portfolio. The company is developing novel small molecule empathogens with potential applications in trauma-related mental health disorders such as PTSD. Awakn's patent strategy, initiated in 2021, has progressed well across multiple jurisdictions:

- United States: Fast-tracked application under examination, with positive evaluations from the International Searching Authority.
- Europe: Application pending, with optimistic prospects for patent granting.
- Canada: Application pending examination, with potential for expedited process.

The European Patent Office examiner has confirmed the pharmaceutical composition and method of use claims for Awakn's lead compounds to be both novel and inventive. This progress indicates a promising path towards securing patent protection for Awakn's innovative therapeutics targeting substance use and mental health disorders.

Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has entered into a commercial collaboration agreement with Graft Polymer (UK) Plc (LON: GPL) to develop Awakn's novel aminoindane new chemical entity series programme. The collaboration aims to develop potential treatments for trauma-related mental health disorders, particularly post-traumatic stress disorder (PTSD).

Key points of the agreement include:

• Graft will initially contribute £300,000 and expertise in novel drug delivery systems
• Awakn will contribute intellectual property and development expertise
• Future funding will be split equally between the companies
• Graft will receive a 40% royalty of future net income generated by the Aminoindane NCEs
• The program will be led by Awakn's Chief Scientific Officer, Prof. David Nutt

Awakn Life Sciences announced the closing of a second tranche of its non-brokered private placement, raising an additional $394,285 by issuing 857,142 units at $0.46 per unit.

Each unit consists of one common share and 0.75 of a common share purchase warrant, allowing purchase of one common share at $0.63 for five years. The proceeds will fund the company's working capital. Securities from the offering are subject to a four-month plus one-day hold period.

The offering is not registered under the U.S. Securities Act and cannot be sold within the United States without proper registration or exemption.